⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10064189 | 1.00 | — | — | |
| SCHEMBL3899323 | 1.00 | — | — | |
| SCHEMBL17142633 | 0.87 | ALDH1A1 (0.47) | — | |
| SCHEMBL721962 | 0.87 | ALDH1A1 (0.47) | — | |
| SCHEMBL17148081 | 0.87 | ALDH1A1 (0.47) | — | |
| SCHEMBL2674136 | 0.87 | PDCD1 (0.44) | — | |
| SCHEMBL12279922 | 0.87 | PDCD1 (0.44) | — | |
| SCHEMBL12280022 | 0.87 | PDCD1 (0.44) | — | |
| SCHEMBL722623 | 0.86 | ALOX15 (0.57) | — | |
| SCHEMBL28960037 | 0.85 | PDCD1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113493628-B | Quantum dot ink and preparation method of quantum dot film | TCL科技集团股份有限公司 | 2023-06-23 | — | — | CN | claimed |
| CN-113493628-A | Quantum dot ink and preparation method of quantum dot film | TCL科技集团股份有限公司 | 2021-10-12 | — | — | CN | claimed |
| EP-3802539-A1 | TETRAHYDRO-1 H-PYRAZINO[2,1 -AJISOINDOLYLQUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-04-14 | — | — | EP | claimed |
| WO-2019233941-A1 | TETRAHYDRO-1 H-PYRAZINO[2,1 -AJISOINDOLYLQUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2019-12-12 | — | — | WO | claimed |
| EP-4058452-B1 | HYDROPYRAZINO[1,2-B]ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2025-07-09 | — | — | EP | disclosed |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2025064718-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-12157746-B2 | Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2024-12-03 | — | — | US | disclosed |
| CN-114728959-B | Hydropyrazino [1,2-b ] isoquinoline compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2024-11-12 | — | — | CN | disclosed |
| US-20240109917-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2024-04-04 | — | — | US | disclosed |
| CN-112204028-B | tetrahydro-1H-pyrazino [2,1-a ] isoindoloquinoline compounds for use in the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2023-12-29 | — | — | CN | disclosed |
| EP-4267585-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | Actelion Pharmaceuticals Ltd (CH) | 2023-11-01 | — | — | EP | disclosed |
| WO-2011043480-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | 田辺三菱製薬株式会社 (JP) | 2011-04-14 | — | — | WO | disclosed |
| WO-2010141539-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2010-12-09 | — | — | WO | disclosed |
| EP-1453501-B1 | N- ARYL-N'-ARYLCYCLOALKYL-UREA DERIVATIVES AS MCH ANTAGONISTS FOR THE TREATMENT OF OBESITY | SCHERING CORP (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7348328-B2 | MCH antagonists for the treatment of obesity | SCHERING CORPORATION (US) | 2008-03-25 | — | — | US | disclosed |
| CN-1617718-A | N-aryl-N'-arylcycloalkyl-urea derivatives as MCH antagonists for the treatment of obesity | SCHERING CORP (US) | 2005-05-18 | — | — | CN | disclosed |
| EP-1453501-A1 | N- ARYL-N'-ARYLCYCLOALKYL-UREA DERIVATIVES AS MCH ANTAGONISTS FOR THE TREATMENT OF OBESITY | SCHERING CORPORATION (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040122017-A1 | MCH antagonists for the treatment of obesity | SCHERING CORPORATION | 2004-06-24 | — | — | US | disclosed |
| WO-2003047568-A1 | N-ARYL-N'-ARYLCYCLOALKYL-UREA DERIVATIVES AS MCH ANTAGONISTS FOR THE TREATMENT OF OBESITY | SCHERING CORPORATION (US) | 2003-06-12 | — | — | WO | disclosed |